6. Parkinson disease
2,123 clinical trials,   2,046 drugs   (DrugBank: 324 drugs),   183 drug target genes,   198 drug target pathways

Searched query = "Parkinson disease"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
3 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT00590122
(ClinicalTrials.gov)
October 200628/12/2007Parcopa Versus Carbidopa-Levodopa in a Single Dose Cross-Over Comparison StudyCOMPARISON OF ORALLY DISSOLVING LEVODOPA (PARCOPA®) TO CONVENTIONAL ORAL LEVODOPA: A SINGLE DOSE, DOUBLE-BLIND, PLACEBO CONTROLLED, CROSS-OVER TRIALParkinson's DiseaseDrug: Parcopa;Drug: carbidopa-levodopaBaylor College of MedicineUCB PharmaCompleted31 Years80 YearsBoth20Phase 4United States
2NCT00139880
(ClinicalTrials.gov)
June 200529/8/2005A Single Center, Randomized, Double-blind, Crossover Pilot Trial Comparing the Onset of Action of Parcopa™ With Sinemet® in Subjects With Stable Parkinson's DiseaseA Single Center, Randomized, Double-blind, Crossover Pilot Trial Comparing the Onset of Action of Parcopa™ With Sinemet® in Subjects With Stable Parkinson's DiseaseParkinson's DiseaseDrug: ParcopaUCB PharmaNULLCompleted40 YearsN/ABothPhase 3United States
3NCT00139867
(ClinicalTrials.gov)
January 200429/8/2005A Multicenter, Open-label Trial to Assess Subject Preference of PARCOPA, Carbidopa/Levodopa Orally Disintegrating Tablets, Compared to Conventional Carbidopa/Levodopa Tablets in Subjects With Stable Parkinson's DiseaseA Multicenter, Open-label Trial to Assess Subject Preference of PARCOPA, Carbidopa/Levodopa Orally Disintegrating Tablets, Compared to Conventional Carbidopa/Levodopa Tablets in Subjects With Stable Parkinson's DiseaseParkinson's DiseaseDrug: PARCOPAUCB PharmaNULLCompleted18 YearsN/ABothPhase 3United States